GSK Aktie
21,67
EUR
±0,00
EUR
±0,00
%
18,73
GBP
-0,14
GBP
-0,72
%
GSK jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Diese Analysten bewerten die GSK-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| Bernstein Research | 26,30 GBP | - | 05.05.2026 | |
| Deutsche Bank AG | 19,00 GBP | - | 30.04.2026 | |
| JP Morgan Chase & Co. | 17,00 GBP | - | 30.04.2026 | |
| Barclays Capital | 18,00 GBP | - | 30.04.2026 | |
| Goldman Sachs Group Inc. | 18,70 GBP | - | 30.04.2026 | |
| DZ BANK | - | - | 29.04.2026 | |
| Jefferies & Company Inc. | 25,00 GBP | - | 13.04.2026 | |
| UBS AG | 19,40 GBP | - | 10.04.2026 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 20,00 GBP | - | 17.02.2026 |
Werbung
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| Bayer | 5 | 5 | 0 | 42,22 EUR | +11,40% |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 2 | 5 | 2 | 20,42 GBP | - |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 4 | 3 | 0 | 139,50 EUR | +15,58% |
| Novartis AG | 2 | 6 | 1 | 119,62 CHF | +2,41% |
| Perrigo Company | 0 | 0 | 0 | - | - |
| Pfizer Inc. | 2 | 5 | 0 | 28,83 USD | +11,61% |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Sanofi S.A. | 4 | 4 | 0 | 96,12 EUR | +31,01% |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |




